Rutgers-CINJ Associate Director for Clinical Research; Distinguished Prof RWJ Med School; Director Onc Research RWJBarnabas Health;
Rutgers-Cancer Inst of NJ
Joined March 2015
- Tweets857
- Following108
- Followers1.1K
- Likes185
See my latest on behalf of AGICC group: FOLFOXIRI & panitumumab for left-sided RAS-wild-type metastatic colorectal cancer academic.oup.com/oncolo/arti…. Triplet chemo & antiEGFR highly effective for molecularly selected pts. Thanks to coauthors & our pts. @RutgersCancer @RWJBarnabas
Published: Pleased to be coauthor, and named study! Chemo & Immunotherapy 👉 improved outcomes for stage III MSI-high #coloncancer. Thanks to co-authors, NRG staff and all participating doctors & patients. @RutgersCancer @RWJBarnabas @NRGonc
ascopubs.org/doi/10.1200/JCO….
Thanks to special lecturer Dr Nancy Kemeny, Emeritus Professor @MSKCancerCenter for her outstanding review of hepatic intra-arterial infusion (HAI) - from a pioneer’s perspective - yesterday @RutgersCancer. 👉Thanks to @RWJBarnabas Foundation & Nick Rentas for supporting this
Howard S Hochster MD retweeted
A huge thank you to the @NFLAlumni for an insightful evening of great conversation about cancer, screenings and survivorship! 💪🏈
@RWJBarnabas
@NFLAlumniNY_NJ
NFL Alumni is proud to join @rwjbarnabas and @rutgerscancer at the Jack & Sheryl Morris Cancer Center for a community conversation on surviving cancer. Thank you to all who joined us to share their insights.
Grateful for @r_oben, @ojanderson24, Ray Lucas, Tony Richardson, @DrAEvens, @DGolombos, @cdcgov
#GearUpAgainstCancer
Howard S Hochster MD retweeted
Don’t miss @RutgersCancer @RWJBarnabas Associate Director for Population Science and Community Outreach as well as our
Director of Cancer Health Equity Center of Excellence, Dr. Anita Kinney, in booth #11025 today at #ASCO26! Learn about the exciting work happening in cancer prevention and population science. ⬇️
Howard S Hochster MD retweeted
I just learned #cancer #surgical icon of the #nonoperativemanagement approach to #rectalcancer Dr. Angelita Habr-Gama just passed away today at the age of 93. She was AMAZING! She has changed our views on the necessity of surgery in the setting of cCR. #groundbreaking #cancerresearch #originaldisruptor
Howard S Hochster MD retweeted
This #ClinicalTrialsDay, we recognize the critical role clinical trials play in advancing cancer care and research. With over 230 active cancer clinical trials, @RutgersCancer is turning these discoveries into new ways to prevent and treat cancer that is shaping the future of cancer care in New Jersey and beyond.
Learn more about cancer clinical trials available through @RutgersCancer and @RWJBarnabas: cinj.org/clinical-trials
Great work @DrAEvens ! Appreciate your expertise and dedication. @RutgersCancer
Congratulations to @RutgersCancer @RWJBarnabas Dr. Andrew Evens @DrAEvens on contributing to newly published international consensus guidelines in the Journal of Clinical Oncology @JCO_ASCO. This landmark publication addresses the management of hematologic cancers during pregnancy and reflects over a year of global collaboration through the International Network on Cancer, Infertility and Pregnancy (INCIP).
Read the publication: ascopubs.org/doi/10.1200/JCO…
Thanks Dr Eng. And also enrolling @RutgersCancer. Amivantamab already approved in lung cancer but hopefully equally effective for RAS non-mutated #coloncancer
Out of press! Amivantamab (fully human, bispecific IgG1 monoclonal antibody) that targets EGFR and MET Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO… @ASCO #colorectalcancer #cancer
Enroll to #Origami2 (NCT06662786) and #Origami3 (NCT06750094) Vanderbilt University Medical Center
Howard S Hochster MD retweeted
Out of press! Amivantamab (fully human, bispecific IgG1 monoclonal antibody) that targets EGFR and MET Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO… @ASCO #colorectalcancer #cancer
Enroll to #Origami2 (NCT06662786) and #Origami3 (NCT06750094) Vanderbilt University Medical Center
Available @RutgersCancer for refractory gastric cancer. Call and we can test you for the KKLC1 antigen and HLA type. @RWJBarnabas #stomachcancer
NOW OPEN @RutgersCancer: “A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.” #ClinicalTrial #CancerResearch @CSHinrichsMD @RWJBarnabas cinj.org/clinical-trials/fin…
👉Great opportunity!! Submit your research 👈
📣 Last call! Submit your proposal on Cancer & Aging to JNCI, exploring mechanisms, interventions & policy for better outcomes. 📅 Deadline: Jan 9, 2026
Learn more: oxford.ly/49jY2mI
@mandel_jeanne @HH_Oncodr @xrtGenomics @minasedrakmd
ALT Graphic promoting a call for proposals on “Stem Cells,” featuring Oxford University Press branding, a microscope in use, and text encouraging researchers to learn more and submit their work.
Howard S Hochster MD retweeted
For the 1 in 20 Americans facing a cancer diagnosis, new hope is not just a wish—it's essential. At @RutgersCancer and @RWJBarnabas, we’re dedicated to pioneering innovative treatments.
Together, we're inching closer to a cure every day!❤️
🔬 Learn more about cancer research happening at @RutgersCancer.
#MicroscopeMonday
We can test your tumor if you have refractory cancer with the diagnoses below. Contact us if you are interested in possibly receiving cellular therapy. @RutgersCancer
NOW OPEN @RutgersCancer: “A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.” #ClinicalTrial #CancerResearch @CSHinrichsMD @RWJBarnabas cinj.org/clinical-trials/fin…
Happy holidays to everyone and especially to our patients @RutgersCancer #MorrisCC. And an especially joyous Holiday of Lights to those observing #Hanukkah. Our wonderful menorah in the #MorrisCC lobby bringing light to all.
Howard S Hochster MD retweeted
Congrats to Mihir Patel on such an impressive accomplishment! @RutgersCancer
Proud of our resident Mihir Patel who received the Cotman scholar award for his presentation at SABCS. @RU_RadOnc @RutgersCancer @RWJMS @BHaffty
Howard S Hochster MD retweeted
On Friday, 12/12, @RutgersCancer @RWJBarnabas Dr. Mridula George @MridulaGeorgeMD presented “OCTANE: Adjuvant liposomal doxorubicin and carboplatin for early-stage triple negative breast cancer” at #SABCS25.
Howard S Hochster MD retweeted
🚨🚨 With 93 peer-reviewed abstract presentations (including 33 podium/oral talks) combined with multiple invited educational talks at #ASH2025, there will be >100 total presentations on cutting edge science & key clinical breakthroughs given by our #bloodcancer and #classicalhematology experts!
Howard S Hochster MD retweeted
The @RutgersCancer @RWJBarnabas Annual Oncology Clinical Practice and Research Summit has started! Oncologists from across the Oncology Service Line will share the latest advancements in their disciplines over two days of enlightening sessions with @DrAEvens kicking off this insightful event! #CANCERNJ2025
Howard S Hochster MD retweeted
Thank you to our panelists Eric Carney, Bill Arnold, Alan Lee, and Rick Davis and moderator Susan Solometo on the @RWJBarnabas Transformative Investment in Oncology Services for a very informative panel session! #CancerNJ2025
@RWJUH @monmouthmedctr @monmouthsouth @CBMCNJ @CommunityMedNJ @rwjhamilton @RWJSomerset
